Search

everythinglearnresearchcommunity

for

Search:↓

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

The document concludes that hormonal biomarkers are key for diagnosing hyperandrogenemia in women and hypogonadism in men.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

Anabolic steroids boost muscle growth, SARMs increase muscle mass and bone density without side effects, and myostatin inhibitors block a protein that stops muscle growth, but each has potential risks.

Early NAS level changes affect alcohol consumption vulnerability.

Older men with lower levels of available testosterone are more likely to be frail.

Thyroid disease can cause hair loss and treating thyroid problems might help with hair disorders.

Hirsutism can be caused by various conditions besides PCOS, and it's important to treat the underlying issue and manage symptoms with medication and cosmetic approaches.

Sebaceous glands play a key role in skin health, immunity, and various skin diseases.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Stress-related hair loss was reversed with a special medication.

Paeonia lactiflora and Poria cocos extracts can potentially increase hair growth and reduce hair loss symptoms by lowering testosterone and inflammation levels.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.

PCOS is a complex disorder in women that can lead to various health risks and requires personalized treatment.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Eating a balanced diet with the right vitamins and minerals is important for healthy hair, but too many supplements can be harmful.

Mouse skin can produce and process serotonin, with variations depending on hair cycle, body location, and mouse strain.

Flutamide, an antiandrogen, has minimal impact on female rat endocrine systems and does not significantly change their reproductive cycles.

Estrogens significantly influence hair growth by interacting with receptors in hair follicles and may help regulate the hair growth cycle.

Hormonal therapy is a treatment option for acne, the only medical treatment for hirsutism, and the most promising for androgenetic alopecia.

Treatment of acromegaly can improve women's reproductive health issues caused by hormonal imbalances or tumors.

IGF-1 may affect hair growth and loss, but more research is needed to confirm effective and safe treatments.

Genetic defects in the glucocorticoid receptor gene can cause conditions with abnormal sensitivity to stress hormones, and other factors may also affect this sensitivity.

Topical L-thyroxine may help with wound healing and hair growth but should be used short-term due to potential risks.

Hormone imbalance is linked to Hidradenitis Suppurativa, a skin condition, and treatments like anti-androgenic therapy and metformin can help. It's also suggested to check patients for insulin resistance and Polycystic Ovary Syndrome.

Hypothyroidism harms rat skin, but topical triiodothyronine may help improve it.

Stress and emotional factors can worsen skin conditions by affecting the immune system.

Mouflon rams mature gradually with changes in body, horns, and hormones linked to age and seasons, reaching full sexual maturity well after puberty.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.